Announcements
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
Atypical medullary breast carcinoma – the clinical picture and prognosis
B. Sas-Korczynska1, *, A. Stelmach2, J. Jakubowicz1, J. Rys3, J.W. Mitus2, P. Skotnicki2, T. Walasek4, M. Reinfus4
Show Less
1
Department of Clinical Oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Krakow, Poland
2
Departmet of Surgical Oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Krakow, Poland
3
Departmet of Pathology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Krakow, Poland
4
Department of Radiotherapy, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Krakow, Poland
Eur. J. Gynaecol. Oncol. 2018, 39(1), 32–36;
https://doi.org/10.12892/ejgo3610.2018
Published: 10 February 2018
Abstract
Purpose: The purpose of this paper was to present the clinical picture and the effectiveness of treatment patients with atypical medullary breast carcinoma (A-MBC). Materials and Methods: Sixty-five patients with A-MBC were treated between 1975 and 2005. More of them (70.2%) were in Stage I or II and had no expression of c-erb-B2 gene (81.5%), estrogen receptor (87.7%), and progesterone receptor (76.9%). Radical mastectomy was applied in 55 patients (84.6%) and remaining ten (15.4%) patients underwent breast conserving therapy. The treatment effectiveness was evaluated as ten-year disease-free survival (DFS) rate (Kaplan-Meier method). Results: The ten-year disease-free survival (DFS) rate was 61.5%. Only lymph nodal status was statistically significant prognostic factor. Ten–year DFS rate was 82.1% and 30.8% for pN0 and pN+, respectively. Conclusion: Although A-MBC has probably a slightly better prognosis than invasive ductal breast carcinoma, these patients should be treated according to the same rules as those with breast cancer of basal-like or triple-negative type.
Keywords
Medullary breast cancer
Atypical medullary breast cancer
Triple-negative breast cancer